Vericel Corporation (VCEL)

Vericel's stock experienced a 52-week range of $63.00 high and $29.24 low. In Q2 2025, total revenue increased 20% to $63.2 million, driven by MACI revenue growth of 21%. In Q3 2025, Vericel reported record total revenue of $67.5 million, with MACI revenue increasing by 25%. Despite positive earnings reports, some analyses indicated a "Near-Term Weak Sentiment" for VCEL, with one report suggesting Vericel's growth plans "may have run out of gas," leading to a rating downgrade. Short interest in Vericel also increased by 4.07% recently, indicating decreasing investor sentiment.

Demand for Vericel's core products, particularly MACI, is generally considered steady. However, the company has acknowledged "variability in burn care revenue" and "potential variability in fourth-quarter performance due to the largest quarter size and year-end holidays."

Vericel Corp. is a biopharmaceutical company focused on patient-specific, expanded cellular therapies within the Healthcare sector, specifically Biotechnology and Pharmaceuticals. Its major products include MACI for cartilage defects, Epicel for burn treatment, and NexoBrid for eschar removal, with North American rights held by Vericel.

Vericel Corp. primarily markets its cell therapy products in the United States and is headquartered in Cambridge, Massachusetts. While its current commercial focus is domestic, Vericel is actively seeking partners for the international commercialization of its MACI and Epicel products outside the United States. All 2025 revenue from NexoBrid is anticipated from domestic sales.

Vericel generally maintains a positive brand reputation for its pioneering work in sports medicine and burn care therapies. However, a "rating downgrade" in January 2026, stemming from concerns about inconsistent growth and fluctuating profitability, could be perceived negatively. Despite these, analyst consensus for VCEL stock remains a "Moderate Buy" with a significant upside potential, indicating underlying confidence in the company's long-term prospects.

Vericel Corporation is a publicly traded company on NASDAQ under the ticker VCEL, with institutional investors holding the majority of its shares. Key institutional shareholders include BlackRock, Inc., The Vanguard Group, Inc., and State Street Corp. Insider ownership, though a smaller percentage, has seen a slight increase, with CEO Dominick Colangelo holding a direct ownership stake valued at $9.21 million.